December 2025 in “Journal of health economics and outcomes research” Alopecia Areata in Saudi Arabia is costly, mainly due to lost work and medication expenses, needing better diagnosis, treatment, and care.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
April 2019 in “Journal of Investigative Dermatology” Frontal Fibrosing Alopecia involves disrupted cholesterol pathways, fibrosis, and increased mast cells.
1 citations
,
November 2023 in “Anais Brasileiros de Dermatologia” Certain gene variations and low adiponectin levels may increase the risk of hair loss in Egyptians.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
December 2024 in “PubMed” Freezia cream helps regrow hair in people with Alopecia Areata.
November 2024 in “Dermatology and Therapy” Dermatologists should carefully choose treatments for FFA to avoid worsening the condition.
19 citations
,
April 2020 in “Dermatologic Therapy” Dutasteride works better than finasteride for hair loss, with both being safe to use.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
1 citations
,
November 2023 in “Journal of Investigative Dermatology” Farudodstat may effectively treat alopecia areata without harming hair follicles.
2 citations
,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
The conclusion cannot be provided because the document content is not available.
January 2004 in “DOAJ (DOAJ: Directory of Open Access Journals)” Finasteride is a safe and effective treatment for male hair loss.
8 citations
,
October 2018 in “Journal of The American Academy of Dermatology” The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
30 citations
,
January 2000 in “Dermatologic Clinics” Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.
January 2023 in “Intisari Sains Medis” Andropause is strongly associated with hair loss in male civil servants.
April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
November 2021 in “Frontiers in Genetics” The FAW-FS algorithm improves depression recognition, and psychological interventions help AGA patients' mental health.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
1 citations
,
April 2024 in “Dermatology Practical & Conceptual” Hair loss in male frontal fibrosing alopecia may spare areas covered by a wristwatch.
August 2020 in “Benha Journal of Applied Sciences” Higher FABP4 levels may help diagnose androgenetic alopecia early.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.